InvestorsHub Logo
Followers 283
Posts 34085
Boards Moderated 0
Alias Born 11/14/2013

Re: exwannabe post# 671283

Friday, 02/09/2024 1:50:03 PM

Friday, February 09, 2024 1:50:03 PM

Post# of 732710
You are arguing out of both sides of your mouth. In the post I’m responding to you totally ignore:

1. That the Eden system is specifically designed for DCVax specifications.
2. That the Eden system will be proven to reach those end product specifications, imo.
3. That the Eden system is patented, and will be further patented to outline the optimization.
4. That NWBO owns Flaskworks.
5. That the end product is DCVax-l.
6. That the end product is protected by biologic exclusive use for ten years from time of approval.
7. That there is data exclusivity for the phase iii trial (safety and efficacy) for five years.
8. That other autologous whole lysate pulsed dendritic therapies are at best several years from obtaining approval.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News